JP2013535508A - 抗体付きアジュバントを抗原提示細胞に直接的に標的化することをベースにした新規ワクチンアジュバント - Google Patents
抗体付きアジュバントを抗原提示細胞に直接的に標的化することをベースにした新規ワクチンアジュバント Download PDFInfo
- Publication number
- JP2013535508A JP2013535508A JP2013524253A JP2013524253A JP2013535508A JP 2013535508 A JP2013535508 A JP 2013535508A JP 2013524253 A JP2013524253 A JP 2013524253A JP 2013524253 A JP2013524253 A JP 2013524253A JP 2013535508 A JP2013535508 A JP 2013535508A
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- cancer
- antibody
- composition
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K2039/106—Vibrio; Campylobacter; Not used, see subgroups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37376310P | 2010-08-13 | 2010-08-13 | |
| US61/373,763 | 2010-08-13 | ||
| PCT/US2011/047633 WO2012021834A1 (en) | 2010-08-13 | 2011-08-12 | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013535508A true JP2013535508A (ja) | 2013-09-12 |
| JP2013535508A5 JP2013535508A5 (cg-RX-API-DMAC7.html) | 2014-09-25 |
Family
ID=45564978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013524253A Pending JP2013535508A (ja) | 2010-08-13 | 2011-08-12 | 抗体付きアジュバントを抗原提示細胞に直接的に標的化することをベースにした新規ワクチンアジュバント |
Country Status (14)
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017507922A (ja) * | 2014-01-22 | 2017-03-23 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 抗体のためおよび抗体が充填された樹状細胞を介した療法のための方法および組成物 |
| JP2017525655A (ja) * | 2014-06-02 | 2017-09-07 | ベイラー リサーチ インスティテュートBaylor Research Institute | アレルギーおよび炎症性疾患を治療するための方法および組成物 |
| JP2019506372A (ja) * | 2015-12-15 | 2019-03-07 | アンスティトゥート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシャルシュ・メディカル・(インセルム) | Ebv細胞抗原及びターゲティング部分を含む免疫原性構築物並びにその適用 |
| JP2020526482A (ja) * | 2017-06-28 | 2020-08-31 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | デクチン−2刺激及び癌免疫療法のための方法及び組成物 |
| US11110178B2 (en) | 2016-07-07 | 2021-09-07 | The Board Of Trustees Of The Leland Standford Junior University | Antibody adjuvant conjugates |
| JP2022518771A (ja) * | 2019-01-22 | 2022-03-16 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 抗原提示好中球由来樹状細胞およびその使用方法 |
| US11400164B2 (en) | 2019-03-15 | 2022-08-02 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
| JP2023502712A (ja) * | 2019-11-21 | 2023-01-25 | インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) | 抗pd-1/il-15免疫サイトカインによる新しいpd-1標的免疫療法 |
| JP2023549555A (ja) * | 2020-11-18 | 2023-11-27 | パイオニア イミュノセラピューティクス インコーポレイテッド | 抗marco抗体及びその使用 |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI422594B (zh) | 2007-02-02 | 2014-01-11 | Baylor Res Inst | 經由樹狀細胞去唾液酸糖蛋白受體(dc-asgpr)接合抗原呈現細胞之藥劑 |
| CN101820910B (zh) * | 2007-05-03 | 2014-08-06 | 新加坡科技研究局 | 结合细胞内prl-1多肽或prl-3多肽的抗体 |
| WO2012122396A1 (en) * | 2011-03-08 | 2012-09-13 | Baylor Research Institute | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells |
| AR088220A1 (es) * | 2011-08-29 | 2014-05-21 | Baylor Res Inst | Activacion de celulas dendriticas humanas por el receptor de dectina-1 o de tipo toll 2 (tlr2) en el control de la alergia y el asma |
| WO2013134293A1 (en) * | 2012-03-05 | 2013-09-12 | Duke University | Vaccine formulation |
| CN112587671A (zh) * | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| WO2014031984A1 (en) * | 2012-08-24 | 2014-02-27 | Baylor Research Institute | Immunological detection methods and compositions |
| WO2014210540A1 (en) | 2013-06-28 | 2014-12-31 | Baylor Research Institute | Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis |
| CN103409451A (zh) * | 2013-06-28 | 2013-11-27 | 扬州维克斯生物科技有限公司 | 一种向树突状细胞dc靶向加载肿瘤抗原肽的方法 |
| AU2014315081A1 (en) | 2013-09-05 | 2016-03-24 | Duke University | Nav1.7 antibodies and methods of using the same |
| EP3092256B1 (en) | 2014-01-10 | 2022-05-18 | Birdie Biopharmaceuticals Inc. | Compounds and compositions for immunotherapy |
| WO2015106281A1 (en) | 2014-01-13 | 2015-07-16 | Baylor Research Institute | Novel vaccines against hpv and hpv-related diseases |
| IL300029A (en) | 2014-05-16 | 2023-03-01 | Baylor Res Institute | Methods and preparations for the treatment of autoimmune and inflammatory conditions |
| MX2016017393A (es) | 2014-07-01 | 2017-09-05 | Pfizer | Diacuerpos heterodimericos biespecificos y sus usos. |
| DK4001311T3 (da) | 2014-07-09 | 2026-02-02 | Birdie Biopharmaceuticals Inc | Anti-pd-l1/pd-1-kombinationer til behandling af tumorer |
| CN112546238A (zh) | 2014-09-01 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
| CN104689313A (zh) * | 2015-03-04 | 2015-06-10 | 中国科学院海洋研究所 | 大菱鲆cd83分子作为疫苗佐剂的应用 |
| US10624964B2 (en) | 2015-05-01 | 2020-04-21 | The Trustees Of The University Of Pennsylvania | Methods and compositions for stimulating immune response using potent immunostimulatory RNA motifs |
| CR20180229A (es) | 2015-10-29 | 2018-08-24 | Novartis Ag | Conjugados de anticuerpos que comprenden un agonista del receptor tipo toll |
| KR102810368B1 (ko) * | 2015-11-10 | 2025-05-19 | 예일 유니버시티 | 자가면역 질환 및 암을 치료하기 위한 조성물 및 방법 |
| CN106943596A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于治疗肿瘤的抗-cd20组合 |
| CN106943598A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于治疗肿瘤的抗-her2组合 |
| CN106943597A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于治疗肿瘤的抗-egfr组合 |
| MX2018010485A (es) | 2016-03-04 | 2019-01-10 | Jn Biosciences Llc | Anticuerpos para inmunoreceptor de celulas t con dominios de ig e itim (tigit). |
| CA3049791A1 (en) * | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| CN108727503A (zh) * | 2017-04-18 | 2018-11-02 | 武汉博沃生物科技有限公司 | VZV重组gE-鞭毛素融合蛋白及其制备方法和应用 |
| CN108794467A (zh) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
| FI3641771T3 (fi) | 2017-06-23 | 2026-08-11 | Birdie Biopharmaceuticals Inc | Farmaseuttisia koostumuksia |
| US20210369635A1 (en) * | 2017-11-29 | 2021-12-02 | Adaptive Phage Therapeutics, Inc. | Novel methods of vaccination using icosahedral phage |
| PE20211456A1 (es) * | 2018-02-28 | 2021-08-05 | Hoffmann La Roche | Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado |
| WO2020193718A1 (en) | 2019-03-27 | 2020-10-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Recombinant proteins with cd40 activating properties |
| WO2020243616A1 (en) * | 2019-05-31 | 2020-12-03 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | E-cadherin activating antibodies and uses thereof |
| US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| US20230183366A1 (en) | 2020-05-13 | 2023-06-15 | Inserm (Institut National De La Santé Et De La Recherch Médicale) | Recombinant proteins with ox40 activating properties |
| CA3184802A1 (en) | 2020-05-26 | 2021-12-02 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes |
| TW202210514A (zh) | 2020-06-02 | 2022-03-16 | 美商阿克思生物科學有限公司 | 針對tigit的抗體 |
| KR20230047361A (ko) | 2020-07-01 | 2023-04-07 | 아르스 파마슈티컬스 인크. | 항-asgr1 항체 접합체 및 이의 용도 |
| CN111850006B (zh) * | 2020-07-27 | 2022-04-22 | 齐鲁工业大学 | 一种适用于低钙离子浓度的纤维小体对接蛋白组合突变体36865及应用 |
| JP2023554587A (ja) | 2020-11-12 | 2023-12-28 | アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) | Sars-cov-2 スパイクタンパク質の受容体結合ドメインにコンジュゲートまたは融合している抗体およびワクチン目的でのそれらの使用 |
| US20240131138A1 (en) | 2020-12-23 | 2024-04-25 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Chlamydia vaccine based on targeting momp vs4 antigen to antigen presenting cells |
| MX2023008986A (es) | 2021-01-29 | 2023-08-15 | Inst Nat Sante Rech Med | Polipeptidos antigenicos de chlamydia trachomatis y usos de los mismos con fines de vacuna. |
| CN118555970A (zh) * | 2021-11-04 | 2024-08-27 | 总医院有限公司 | 抗间皮素抗体试剂 |
| JP2024540505A (ja) | 2021-11-17 | 2024-10-31 | アンスティチュート、ナシオナル、ドゥ、ラ、サンテ、エ、ドゥ、ラ、ルシェルシュ、メディカル | ユニバーサルサルベコウイルスワクチン |
| CN119948059A (zh) | 2022-10-05 | 2025-05-06 | 法国国家健康医学研究院 | 靶向dc的抗尼帕病毒感染疫苗 |
| EP4601682A1 (en) * | 2022-10-13 | 2025-08-20 | The Brigham & Women's Hospital, Inc. | Methods and compositions for improving response to immunotherapy |
| KR102878250B1 (ko) * | 2023-01-11 | 2025-10-31 | 서울대학교산학협력단 | 코리스메이트 뮤테이즈 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 포함하는 암 예방 또는 치료용 조성물 |
| EP4695289A1 (en) * | 2023-04-13 | 2026-02-18 | The Regents of the University of California | Isoform-independent antibodies to lipoprotein(a) |
| WO2026139467A1 (en) | 2024-12-23 | 2026-07-02 | Institut National de la Santé et de la Recherche Médicale | Methods for producing vesicles and applications thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006502080A (ja) * | 2001-11-27 | 2006-01-19 | シェーリング コーポレイション | 腫瘍由来樹状細胞阻害因子アンタゴニストおよびToll様レセプターアゴニストの併用を使用する、癌を処置するための方法 |
| WO2007103048A2 (en) * | 2006-03-01 | 2007-09-13 | Regents Of The University Of Colorado | Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity |
| WO2008097866A2 (en) * | 2007-02-02 | 2008-08-14 | Baylor Research Institute | Vaccines based on targeting antigen to dcir expressed an antigen-presenting cells |
| JP2013525496A (ja) * | 2010-05-07 | 2013-06-20 | ベイラー リサーチ インスティテュート | ヒトcd8+t細胞の樹状細胞免疫受容体(dcir)媒介クロスプライミング |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1057915C (zh) * | 1994-09-19 | 2000-11-01 | 中国医学科学院医药生物技术研究所 | 免疫佐剂 |
| US9259459B2 (en) * | 2003-01-31 | 2016-02-16 | Celldex Therapeutics Inc. | Antibody vaccine conjugates and uses therefor |
| ES2555544T3 (es) * | 2006-03-07 | 2016-01-04 | Vaxinnate Corporation | Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas |
| TWI423985B (zh) * | 2007-02-23 | 2014-01-21 | 貝勒研究協會 | 利用dectin-1活化人類抗原呈現細胞之醫療應用 |
| US8236318B2 (en) * | 2007-11-07 | 2012-08-07 | Celldex Therapeutics Inc. | Antibodies that bind human dendritic and epithelial cell 205 (DEC-205) |
| WO2010009346A2 (en) * | 2008-07-16 | 2010-01-21 | Baylor Research Institute | Hiv vaccine based on targeting maximized gag and nef to dendritic cells |
| BRPI1009455A2 (pt) * | 2009-03-10 | 2016-03-01 | Baylor Res Inst | anticorpos anti-c40 e usos dos mesmos |
| CN108373509A (zh) * | 2009-03-10 | 2018-08-07 | 贝勒研究院 | 靶向抗原呈递细胞的抗病毒疫苗 |
| BRPI1009454A2 (pt) * | 2009-03-10 | 2019-09-24 | Baylor Res Institute | vacinas contra o câncer direcionadas a células apresentadoras de antígenos |
-
2011
- 2011-08-12 KR KR1020137006354A patent/KR20130108295A/ko not_active Withdrawn
- 2011-08-12 US US13/208,993 patent/US20120039916A1/en not_active Abandoned
- 2011-08-12 CA CA2807585A patent/CA2807585A1/en not_active Abandoned
- 2011-08-12 RU RU2013110889/10A patent/RU2013110889A/ru unknown
- 2011-08-12 JP JP2013524253A patent/JP2013535508A/ja active Pending
- 2011-08-12 AU AU2011289234A patent/AU2011289234B2/en not_active Ceased
- 2011-08-12 TW TW100128970A patent/TWI506035B/zh not_active IP Right Cessation
- 2011-08-12 BR BR112013002940A patent/BR112013002940A2/pt not_active IP Right Cessation
- 2011-08-12 MX MX2013001527A patent/MX2013001527A/es not_active Application Discontinuation
- 2011-08-12 WO PCT/US2011/047633 patent/WO2012021834A1/en not_active Ceased
- 2011-08-12 AR ARP110102955A patent/AR082686A1/es not_active Application Discontinuation
- 2011-08-12 CN CN2011800489046A patent/CN103328005A/zh active Pending
- 2011-08-12 EP EP11817128.9A patent/EP2603235A4/en not_active Withdrawn
-
2013
- 2013-02-06 ZA ZA2013/01013A patent/ZA201301013B/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006502080A (ja) * | 2001-11-27 | 2006-01-19 | シェーリング コーポレイション | 腫瘍由来樹状細胞阻害因子アンタゴニストおよびToll様レセプターアゴニストの併用を使用する、癌を処置するための方法 |
| WO2007103048A2 (en) * | 2006-03-01 | 2007-09-13 | Regents Of The University Of Colorado | Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity |
| WO2008097866A2 (en) * | 2007-02-02 | 2008-08-14 | Baylor Research Institute | Vaccines based on targeting antigen to dcir expressed an antigen-presenting cells |
| JP2013525496A (ja) * | 2010-05-07 | 2013-06-20 | ベイラー リサーチ インスティテュート | ヒトcd8+t細胞の樹状細胞免疫受容体(dcir)媒介クロスプライミング |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017507922A (ja) * | 2014-01-22 | 2017-03-23 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 抗体のためおよび抗体が充填された樹状細胞を介した療法のための方法および組成物 |
| JP2017525655A (ja) * | 2014-06-02 | 2017-09-07 | ベイラー リサーチ インスティテュートBaylor Research Institute | アレルギーおよび炎症性疾患を治療するための方法および組成物 |
| JP2019506372A (ja) * | 2015-12-15 | 2019-03-07 | アンスティトゥート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシャルシュ・メディカル・(インセルム) | Ebv細胞抗原及びターゲティング部分を含む免疫原性構築物並びにその適用 |
| US11147868B2 (en) | 2015-12-15 | 2021-10-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Immunogenic construct comprising an EBV-cell antigen and a targeting moiety and applications thereof |
| US11547761B1 (en) | 2016-07-07 | 2023-01-10 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody adjuvant conjugates |
| US11110178B2 (en) | 2016-07-07 | 2021-09-07 | The Board Of Trustees Of The Leland Standford Junior University | Antibody adjuvant conjugates |
| JP2020526482A (ja) * | 2017-06-28 | 2020-08-31 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | デクチン−2刺激及び癌免疫療法のための方法及び組成物 |
| JP2022518771A (ja) * | 2019-01-22 | 2022-03-16 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 抗原提示好中球由来樹状細胞およびその使用方法 |
| JP7670614B2 (ja) | 2019-01-22 | 2025-04-30 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 抗原提示好中球由来樹状細胞およびその使用方法 |
| US12589140B2 (en) | 2019-01-22 | 2026-03-31 | The Brigham And Women's Hospital, Inc. | Antigen-presenting neutrophil-derived dendritic cells and methods of use thereof |
| US11400164B2 (en) | 2019-03-15 | 2022-08-02 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
| JP2023502712A (ja) * | 2019-11-21 | 2023-01-25 | インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) | 抗pd-1/il-15免疫サイトカインによる新しいpd-1標的免疫療法 |
| JP2023549555A (ja) * | 2020-11-18 | 2023-11-27 | パイオニア イミュノセラピューティクス インコーポレイテッド | 抗marco抗体及びその使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103328005A (zh) | 2013-09-25 |
| BR112013002940A2 (pt) | 2019-09-24 |
| TWI506035B (zh) | 2015-11-01 |
| US20120039916A1 (en) | 2012-02-16 |
| EP2603235A4 (en) | 2014-04-09 |
| AR082686A1 (es) | 2012-12-26 |
| TW201208696A (en) | 2012-03-01 |
| KR20130108295A (ko) | 2013-10-02 |
| EP2603235A1 (en) | 2013-06-19 |
| ZA201301013B (en) | 2015-10-28 |
| AU2011289234B2 (en) | 2014-09-11 |
| WO2012021834A1 (en) | 2012-02-16 |
| AU2011289234A1 (en) | 2013-02-21 |
| RU2013110889A (ru) | 2014-09-20 |
| MX2013001527A (es) | 2013-04-24 |
| CA2807585A1 (en) | 2012-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2011289234B2 (en) | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells | |
| US20120231023A1 (en) | Novel Vaccine Adjuvants Based on Targeting Adjuvants to Antibodies Directly to Antigen-Presenting Cells | |
| US20120121592A1 (en) | Targeting Antigens to Human Dendritic Cells Via DC-Asialoglycoprotein Receptor to Produce IL-10 Regulatory T-Cells | |
| TWI423985B (zh) | 利用dectin-1活化人類抗原呈現細胞之醫療應用 | |
| JP2022000047A (ja) | T細胞療法用のt細胞を調製する方法 | |
| TWI422594B (zh) | 經由樹狀細胞去唾液酸糖蛋白受體(dc-asgpr)接合抗原呈現細胞之藥劑 | |
| JP6109800B2 (ja) | 最大限のgag及びnefを樹状細胞に対して標的化することに基づくhivワクチン | |
| TW201305193A (zh) | 靶向結核病(tb)疫苗之樹突細胞(dc) | |
| US20110274653A1 (en) | Dendritic cell immunoreceptors (dcir)-mediated crosspriming of human cd8+ t cells | |
| CN106687122B (zh) | β-葡聚糖与影响肿瘤微环境的抗癌剂的组合 | |
| US20020187131A1 (en) | Enhanced antigen delivery and modulation of the immune response therefrom | |
| CN102711824A (zh) | 针对朗格汉斯细胞的疫苗 | |
| KR20090127886A (ko) | 수지상 세포 렉틴 유사 산화된 ldl 수용체-1(lox-1)을 통한 사람 항원제시세포의 활성화 | |
| CA2831294A1 (en) | Compositions and methods to immunize against hepatitis c virus | |
| TW201317003A (zh) | 經由戴克丁-1(dectin-1)或類鐸(toll-like)受體2(tlr2)活化人類dc以控制過敏及氣喘 | |
| JP7750525B2 (ja) | 新規なtlr9アゴニスト | |
| US20130017151A1 (en) | SUBSETS OF ANTIGEN-PRESENTING CELLS (APCs) IN THE HUMAN VAGINA AND THEIR DISTINCT FUNCTIONS | |
| TW201219053A (en) | Targeting antigens to human dendritic cells via DC-asialoglycoprotein receptor to produce IL-10 regulatory T-cells | |
| WO2025208068A2 (en) | T cell receptor constructs and uses thereof | |
| HK1185792A (en) | Dendritic cell immunoreceptors (dcir)-mediated crosspriming of human cd8+t cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130703 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140808 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140808 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150806 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160105 |